In 10/2018 we published rpact 1.0.0, a comprehensive package that enables the simulation and analysis of parallel group designs with continuous, binary, and survival endpoint. This package can be downloaded per CRAN and stands under the "GNU Lesser General Public License" version 3. In rpact particularly, the methods described in the recent monograph of Wassmer and Brannath (published by Springer, 2016) are implemented and made available for the public.
In 05/2019 we published rpact 2.0.0 containing lots of new features, e.g.:
- Power calculation at given or adapted sample size for means, rates and survival data
- Sample size and power calculation for survival trials with piecewise accrual time and intensity
- Sample size and power calculation for survival trials with exponential survival time, piecewise exponential survival time and survival times that follow a Weibull distribution
- Simulation tool for survival trials; our simulator is very fast because it was implemented with C++. Adaptive event number recalculations based on conditional power can be assessed
- Simulation tool for designs with continuous and binary endpoints. Adaptive sample size recalculations based on conditional power can be assessed
- Comprehensive and unified tool for performing sample size calculation for fixed sample size design
- Enhanced plot functionalities
Further developments (e.g., multi-armed and enrichment designs) are planned for near future.
The simulation based evaluation of operating characteristics of adaptive designs are becoming increasingly important, and the package addresses this issue. We developed these simulations for the most relevant types of endpoints (continuous, binary, and survival) and included the assessment of sample size reassessment strategies based on conditional power, of futility rules and other strategies. As adaptive strategies classical group sequential tests, combination tests (inverse normal, Fisher's combination test), and adaptive tests based conditional rejection probability (CRP) principle are available.
A comprehensive output in form of summaries, graphs and tables is provided. Additionally, a specific methodology for survival endpoints with adaptation based on surrogates is available.
For the analysis and execution of an adaptive trial, all methods provided by the simulation are available. Specific results of the adaptive methodology are also available, e.g., overall confidence intervals and p-values and conditional and predictive power assessments. The R package is fully integrated in R (i.e., no "stand alone" package) such that R specific data entry, transformations, and summary statistics can be utilized.
The R package rpact is a fully documented and validated product, including
- user requirements specification,
- functional specification,
- technical design specification,
- test plan,
- installation guides,
- user guides, and
- release notes.
The validation of the R package was done compliant to FDA/GxP guidelines and to the validation process of “Base R” and “Recommended Packages” as described in: “R: Regulatory Compliance and Validation Issues, A Guidance Document for the Use of R in Regulated Clinical Trial Environments” (The R Foundation for Statistical Computing, December, 2014). The validation documentation is customized and is licensed for exclusive use by our Prime SLA customers.
Please visit www.rpact.org to get more information about the package.